Scarica l'app Stockscreener
35.33
0.30%
0.085
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Transcript : Ionis Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? - Yahoo Finance
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed - simplywall.st
Transthyretin Amyloid Cardiomyopathy Treatment Market Deep Research ReportPfizer, Ionis Pharmaceuticals - openPR.com
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Pharmaceuticals’ SWOT analysis: RNA therapeutics firm faces pivotal year for stock - Investing.com
Angioedema Treatment Market Insights and Forecast from 2025 - openPR.com
Hereditary Angioedema Drugs Market 2034: EMA, PDMA, FDA - openPR.com
Ionis’ olezarsen shows new promise with strong Phase III results - The Pharma Letter
December 2027 Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis reports success in olezarsen trial for high triglycerides - Yahoo
Treatment-Resistant Hypertension Market: Epidemiology, - openPR.com
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from HC Wainwright - Defense World
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Transcript : Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 08 - marketscreener.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Janus Henderson Group PLC - Defense World
Ionis reports positive data from study of olezarsen for hypertriglyceridemia - Clinical Trials Arena
Ionis Pharmaceuticals (IONS) Receives Buy Rating from HC Wainwri - GuruFocus
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts - Benzinga
In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes - insights.citeline.com
Ionis reports positive results for olezarsen in study By Investing.com - Investing.com South Africa
Ionis reports positive results for olezarsen in study - Investing.com Australia
Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study - HCPLive
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides - BioSpace
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Ionis Pharmaceuticals Says Olezarsen Trial Meets Primary Endpoint, All Key Secondary Endpoints - marketscreener.com
Ionis Pharmaceuticals (IONS) Reports Positive Results from Olezarsen Study | IONS Stock News - GuruFocus
Ionis announces positive topline results from Essence study of o - GuruFocus
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides | IONS Stock News - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stake Reduced by Comerica Bank - Defense World
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Transcript : Ionis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 09 - marketscreener.com
Familial Chylomicronemia Syndrome Drugs Market Size in 7MM - openPR.com
Polycythemia Vera Drugs Market Size in 7MM is expected to grow at - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Insider Monkey
Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential - Insider Monkey
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance
Ionis to host 2025 virtual Annual Meeting of Stockholders | IONS Stock News - GuruFocus
Ionis to host 2025 virtual Annual Meeting of Stockholders - Business Wire
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN
1.30%
3.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):